AGIOAgios Pharmaceuticals, Inc.

Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.

Agios reports $44.7 million in Q2 mitapivat revenue and FDA priority review for sickle cell disease, while advancing pipeline diversification with cevidoplenib.

Agios Pharmaceuticals (NASDAQ:AGIO) reported second-quarter 2026 mitapivat net revenue of $44.7 million, including $40.9 million in the United States and $3.8 million outside the U.S., as the company continued the U.S. thalassemia launch of AQVESME and prepared for a potential sickle cell disease ap

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +9.14% and +97.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

In July 2026, Agios Pharmaceuticals reported topline Phase 2 results for tebapivat in sickle cell disease, showing hemoglobin and hemolysis improvements but insufficient differentiation versus placebo, and consequently decided to discontinue tebapivat’s development for this use. At the same time, Agios highlighted that the FDA had already accepted its supplemental New Drug Application for mitapivat in sickle cell disease under Priority Review, keeping a PK activator path in this indication...

HRMY, ACAD, BIIB, INSM and AGIO are set to report Q2 results, with positive Earnings ESPs suggesting potential earnings surprises.

Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.

NBIX heads into Q2 results with a focus on Ingrezza sales, Crenessity growth and pipeline updates as investors watch key commercial and clinical progress.

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.

Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled.

This deals another blow to tebapivat’s development prospects following its May 2026 termination in MDS due to efficacy concerns.

The biotech firm said it will discontinue development of its therapy for sickle cell disease following the outcome of a Phase 2 trial.

Stock drops after development setbackAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares fell 14% on Tuesday after the company announced it will discontinue development of tebapivat for sickle cell disease following results from a Phase 2 clinical trial.

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.